Rajendran R, Rajendran V, Giraldo Velasquez M, Megalofonou F, Gurski F, Stadelmann C, et al. Oligodendrocyte-Specific Deletion of FGFR1 Reduces Cerebellar Inflammation and Neurodegeneration in MOG35-55-Induced EAE. Int J Mol Sci. 2021;22: pubmed publisher

Hori A, Shimoda M, Naoi Y, Kagara N, Tanei T, Miyake T, et al. Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer. Breast Cancer Res. 2019;21:88 pubmed publisher

Angiolini F, Belloni E, Giordano M, Campioni M, Forneris F, Paronetto M, et al. A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing. elife. 2019;8: pubmed publisher

Zarczynska I, Gorska Arcisz M, Cortez A, Kujawa K, Wilk A, Skladanowski A, et al. p38 Mediates Resistance to FGFR Inhibition in Non-Small Cell Lung Cancer. Cells. 2021;10: pubmed publisher

Kitowska K, Gorska Arcisz M, Antoun D, Zarczynska I, Czaplinska D, Szczepaniak A, et al. MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells. Front Oncol. 2021;11:633410 pubmed publisher

DiGiacomo J, Godet I, Trautmann Rodriguez M, Gilkes D. Extracellular Matrix-Bound FGF2 Mediates Estrogen Receptor Signaling and Therapeutic Response in Breast Cancer. Mol Cancer Res. 2021;19:136-149 pubmed publisher

Wöhrle S, Weiss A, Ito M, Kauffmann A, Murakami M, Jagani Z, et al. Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors. PLoS ONE. 2013;8:e77652 pubmed publisher

Guagnano V, Kauffmann A, Wöhrle S, Stamm C, Ito M, Barys L, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2:1118-33 pubmed publisher

Marshall M, Hinz T, Kono S, Singleton K, Bichon B, Ware K, et al. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res. 2011;17:5016-25 pubmed publisher